|
WO2021068432A1
|
|
Application of elapidae snake postsynaptic neurotoxin monomer molecule in treatment of alzheimer's disease
|
|
CN111467479A
|
|
Application of monomeric molecule of postsynaptic neurotoxin of snake in Elapidae family in treating senile dementia
|
|
CN111000984A
|
|
Application of snake nerve growth factor and snake nerve growth factor precursor in treating senile dementia
|
|
CN111135288A
|
|
Application of cobra neurotoxin monomer molecule in treating senile dementia
|
|
CN110755603A
|
|
Application of cobra neurotoxin polypeptide molecule in treating nephritic proteinuria
|
|
CN110772631A
|
|
Application of cobra neurotoxin molecules with high affinity to nicotinic acetylcholine receptor and rapid effect in analgesia
|
|
CN110478473A
|
|
Cobratoxin polypeptide is to the inhibition of the hyperalgia of opium similar drug and tolerance and to its analgesic synergistic function
|
|
CN110193078A
|
|
One group of pharmaceutical composition and its carrier and dosage form for Cobratoxin intranasal administration
|
|
CN110090296A
|
|
One group has application of the Cobratoxin molecule of high affinity energy quick acting in analgesia with nicotinic acetylcholine receptor
|
|
CN104116746A
|
|
Panaxoside composition as well as preparation method and application thereof
|
